A method of treating polielementnom in patients with clinical manifestations zinkeviciene states

 

(57) Abstract:

The invention relates to medicine, in particular to the treatment of polielementnom in patients with clinical manifestations of zinc status. This suggests the introduction of alzola at a dose of 30 to 120 mg per day orally for 10 - 20 days 2 - 3 courses with an interval of 7 to 10 days. table 1.

The invention relates to medicine, namely to prevention and therapy of diseases caused by or related to polielementnom, in particular with zinc deficiency in the body, with clinical manifestation.

The diagnosis zinkeviciene state" is in fact the case, if the content of zinc in the blood of less than 13 μm/l, even more low concentration of this element in the serum (8,2+/-0,9 μm/l) is an adverse prognostic sign, or when the content of zinc in hair less than 120 µg/g in combination with specific clinical symptoms.

First zinkevicius state in humans were identified as a syndrome of hypogonadism and dwarfism in young Egyptians and Iranians Prasad, who is currently disease called Prasad. Since zinc deficiency is accompanied by many human diseases, we have developed a classification zincke in human tissues for effective treatment of many diseases and syndromes.

It is known that zinkevicius condition is most common among children, pregnant women, in particular, has been shown in population studies that about 30% of children suffer from zinc deficiency.

In children with cinemia slowed growth, less weight gain, reduced resistance to infections and allergens, slower to heal scrapes, wounds, burns, etc.

Significant is another side zinkeviciene conditions, when the relative norm of the content of zinc in the tissues of the observed excess of other trace elements, among which the most important copper.

It is known that copper and zinc are antagonists as for the suction and biological action. Copper concentration in the blood is increased in acute and chronic inflammatory diseases, schizophrenia, alcoholism, rheumatoid arthritis, bronchial asthma, kidney disease, liver, certain types of anemia, Hodgkin's disease, leukemia, after extensive surgical interventions, that is, when there is generally a deficiency of zinc.

One of the manifestations of excess copper hereditary nature of the disease Wilson-Konovalov typical extrapyramidal Imprimerie D-penitsillamin, in turn requiring correction zinc. Consequently, a very large group of diseases of various pathophysiological nature requires the normalization of the trace element composition of the tissues of the human body, including (trace elements) one of the most important is zinc.

Abroad for treatment zinkeviciene States are dozens of drugs, among which, for example, the following: Unizink (Kohler-Plarma), Zinkglukona (Worwag), Zinkorotat-20/40 (Uzsaphrm), Zinterol (Polfa), (ZnSO4x HN2O) (tablets), a variety of drugs with a balanced set of microelements.

In practice in our country, zinc (zinc oxide, zinc sulfate) is used for the treatment zinkeviciene States.

The disadvantage of zinc sulfate as a drug for the treatment of zinkeviciene States is the poor absorption of zinc, i.e., low bioavailability. Increasing doses of the drug can lead to vomiting, drowsiness, increase in the activity of lipase serum and salivary amylase, which limits the use of zinc sulfate as a means of therapy zinkeviciene States.

Problem solving therapy polielementnom, including zinkeviciene States may PU the situation and by application.

In the proposed method, azizol shows new properties that are not described for this medication before, that provides unexpected for clinical practice the results, namely the treatment of disorders of the balance of macro - and microelements (polielementnom), showing synergism (potentiation) to vitamins and other drugs in the regulation of metabolism.

Azizol known hitherto only as a drug for the relief of acute carbon monoxide poisoning. Thus it is recommended that parenteral dose of 60 mg once or in very severe poisoning repeat dose after 1-2 hours

Azizol being a complex organic compound of zinc, was used by the authors of the proposal as the drug of choice among the other compounds of zinc (zinc oxide ZnO, zinc sulfate ZnS4) domestic production. Zinc supplements manufactured in pharmacies by prescription, are the organic compounds of zinc.

The results of clinical trials (about a thousand cases) showed an unexpected result, namely the ability to succeed when polielementnom different etiology and clinical manifestations. The authors suggest that this effect is due to the following ü block toxic radicals NO2, peroxide radicals and others, the ability to stabilize cell membranes;

by changing the constants hill to improve the delivery of oxygen to the cells and increase the efficiency of oxidative phosphorylation (antihypoxic action of alzola is implemented not only when the carbon monoxide poisoning Himicheskaya hypoxia, but also in other types of hypoxia: gistologicheskoe, hypobaric, mixed);

sedative, anticonvulsant action of alzola thanks imidazole component in the product;

the property alzola to strengthen the immune system has been confirmed as the clinic and in the experiment; immunostimulatory properties alzola primarily due to the imidazole part of the drug.

As you know, many systemic diseases are accompanied by hypoxic damage, which in varying degrees lead to impaired brain function and particularly sensitive to hypoxia system pituitary-hypothalamus, responsible for the preservation of autonomic functions, including water-salt metabolism. Possessing antioxidant, antihypoxic effect, Aziza has a positive effect on the indicators of the autonomic and Central nervous system is idocument and effectiveness of water - and fat-soluble vitamins (especially carotenoids).

Clinically this is implemented in the form of effective therapy of diseases very broad profile.

The obtained results give grounds to recommend azizol as a universal means (wide profile) for the treatment of not only zinkeviciene States, which usually manifestirutaya clinical manifestations, but also other accompanying these States, polielementnom.

Comparative study of alzola with other drugs zinc (zinc oxide, orotate zinc, zinc gluconate, zinc-composers - tion) showed that such properties inherent only in azizoglu (table 1).

The results suggest that the effectiveness of the treatment is not a simple function of the dose received by the patient zinc and duration of the course, but is determined and a number of other factors associated with the composition of the drug, as the efficiency of import of organic zinc, to our knowledge, not much higher than the efficiency of zinc oxide at high risk of allergic reactions (especially for zinc-orotata).

It should be noted that significant clinical efficacy of alzola manifests at a much lower dose of zinc, less the duration of the course, and that itself is

P R I m e R 1. Patient F. 35 years, the diagnosis of alopecia areata. History: his mother total alopecia for 40 years, the patient F. after birth began to hair loss, a history of gastritis, acute pancreatitis and goiter I-th degree, dyskinesia of the biliary tract, the relative hyperglycemia, increased anxiety, high meteosensitivity. Patient F. was treated about alopecia with zinc oxide. In the course of treatment has been little overgrown spots, treatment was associated with symptoms of dyspepsia (March-July 1992).

After contacting SRC "Item" patient F. 17.09.92 was performed elemental analysis of hair. The results showed that patient F. reduced the potassium content in the range of 2.2-2.6 times, magnesium 1.5-1.8 times that of manganese in 2-2,5 times, sodium 1.5-1.8 times, zinc, 1.2-1.3 times, which allowed along with the clinical picture to confirm the diagnosis of polylaminate and linkdetector state with dysfunction of the thyroid gland, pituitary gland and the pancreas.

Outpatients received the following course: 1) azizal 1 ampoule per day (60 mg) orally for 10 days, then break for 10 days and a second course of alzola 10 days; to normalize the levels of calcium, potassium and magnesium: 2) calcium chloride 1 ampoule in deede 2-3 times a day for 15 days: 4) multivitamin 1 tablet 1 time per day. The diet is recommended to expand the intake of pumpkin seeds, mushrooms, nuts, onions, eggs, meat, krill, squid.

During the course of alzola and by the early 20th day of the course showed a significant increase efficiency, increased mood, the disappearance of pain in the stomach, the complete obliteration of two small lesions on the forehead and in the left temporal region, on the crown and nape large pockets began to be covered with hair, increased appetite, felt the taste of food, stopped paresthesias in the morning, there was no need in taking Pancreatin and shpy, normalized blood sugar levels.

The effect of the drug survived 30 days after completion of the course of alzola, which indicates the absence of this drug withdrawal syndrome, with no negative effects when taking alzola were noted.

Thus, the reception of alzola inside of this scheme (h + h with a break of 10 days) was effective for the treatment of alopecia areata and its accompanying symptoms. Biochemical effect of the drug was confirmed according to the clinical blood analysis: normalization of glucose levels and alkaline phosphatase activity (a marker of zinc deficiency).

P R I m e is n, treated with antibiotics, and then developed a dysbacteriosis with chronic constipation.

After contacting SRC "Item" patient was performed elemental analysis of hair: decreased levels of zinc 2.5-2.6 times compared to the age norm, a reduced phosphorus content, increased cadmium (upper limit) when the relative norm of the other elements that together with the observed clinical picture corresponds to polielementnom and synchromy of zinc deficiency moderate extent (allergodermatozy, reduction of T-cell immunity, hyperactivity, mental retardation, susceptibility to hair loss). Observed in this case, the excess cadmium adversely affects the kidneys, mental and physical development, promotes removal of zinc from the body.

Patient L. was assigned azizol 1/3 capsules (20 mg) orally 1 time a day for 18 days, externally application zincalloy ointment on the areas of skin itching (3-4 weeks), Oraza 1/2 teaspoon 2 times a day during meals.

2 weeks after initiation of therapy with etizolam decreased hyperactivity disorder, the child has become less irritable, better sleep, virtually disappeared skin rash, missing papules what atom, there has been a sharp improvement in clinical symptoms, which testifies to the efficacy of arizola.

After completing the course of alzola re was carried out elemental analysis of hair of the patient L. the results of which showed a reduction in the level of cadmium to mid norms, increase phosphorus and potassium, the relative decrease in the level of magnesium and zinc.

P R I m e R 3. Patient P. 5 years. Diagnosis: organic lesion of the Central nervous system with elements of seizures. The lag in the psycho-physical development. After otitis increased muscle tone, appeared convulsive attacks, repeatedly hospitalized about seizures.

Recent hospitalization with a diagnosis of epileptic syndrome, spastic tetraparesis, delayed psychomotor development, ketoacidosis. History: 2 years exudative diathesis. Patient P. received treatment: clonazepam, luminal, phenytoin, convulex, radedorm, diacarb, pyridoxal phosphate, calcium gluconate.

When contacting SRC "Item" patient P. was performed elemental analysis of hair and urine. When analysing the hair is registered high content of copper in the 8-9%, calcium 1.3-1.5 times, phosphorus 1.4-1.6 times that of iron at the lower limit of the norm, other elements in norm>The data obtained indicate that the patient P. the disturbed metabolism of trace elements politicalarena upset the balance of calcium, magnesium, phosphorus, copper and zinc, which, together with the clinical picture suggest the disruption of the processes of myelination in the Central nervous system, catecholamines metabolism, metabolism of connective tissue and the liver, which is typical, for example, for disease Wilson-Konovalov, cerebral palsy and other organic lesions of the Central nervous system.

Considering centurie patient P. recommended the use of alzola using hepatoprotector (cars), and homeopathic therapy. Azizol was made according to the scheme: 1 ampoule (60 mg) in 2 doses for 3 days (inside), followed by 0.5 mg (inside) within 14 days, Kars 0.5 tablets 2 times a day for 45-60 days.

On day 2 after starting alzola stopped involuntary movement of arms and legs, appetite improved during the whole period of treatment. Patient P. began to chew and normally her to swallow. The patient became normal to keep your head, reduced hypertonicity of the muscles of the arms, legs and torso with a change in posture, disappeared phenomenon dermatitis.

The results of therapy etizolam indicate that this drug is effective in helping e R 4. Patient A. 30 years. Diagnosis: oily seborrhea, acne, itchy skin, hyperhidrosis of the palms of the hands, excessive sweating, fatigue.

When contacting SRC "Element" was performed elemental analysis of hair, the results of the analysis showed that in the hair of the patient reduced the potassium content in 2-2,3 times, zinc, 1.2-1.3 times, calcium 2-2,3 times. These changes are characteristic of individuals with symptoms of asthenic syndrome, autonomic neuropathy, disorders of metabolism and conduction in the myocardium, metabolic processes in the skin.

Diagnosis: polysemantic and zinkeviciene state srednekovoi degree. Recommended: for metabolism of potassium potassium orotate, lipid metabolism lipocerin, glitsiram, Complivit. To normalize the metabolism of zinc and zincability processes azizol according to the scheme: 1 ampoule (60 mg) orally for 10 days, 10 days off, 10 days on 1 ampoule inside (November 1992).

In the process of taking the drug (azizul) marked improvement in 3-5 days the first year, sharply decreased fatigue, increased activity, disappeared skin rash, decreased itching, withdrawal Syndrome alzola not registered, within 30 days after completion of the course of alzola fatigue below the skin condition nor is S="ptx2">

After contacting SRC "Element" was made elemental semen analysis, which showed a decrease in the zinc content of 6-15 times, phosphorus 1.3-1.4 times that of copper in 2-2,5 times that of manganese in 2-2,5 times, lead to the upper limit of normal.

The obtained data indicate a decline in fertility. These spermatogonia showed 79% of active sperm, no slobodien and 21% stationary and forms from 18 to 25 in the field of view, the number of sperm 2 ml.

Patient recommended: receiving alzola 1 ampoule a day inside (10 vials), fosfaden 2 pellets inside, Complivit on 1 tablet 2 times a day after meals (within 1.5 months).

After a course of arizola was made spermatogonia, which shows the following data: active sperm 82% low 15% inactive 3% and 1-2 in the field of view, the number of sperm in 3.5 ml.

The results showed that after a course of alzola (shortened) objectively improved spermatogenesis, which almost normalized given all of the other indicators.

The table shows the comparative characteristics of the drug zinc in the treatment of polielementnom.

Thus, the data obtained St the LCD mental and physical development in children, and other diseases of complex etiology, in one degree or another related polielementnom and zinc deficiency.

Further, widespread use of alzola in various pathological conditions and in different environmental situations will determine its place among the products of metabolic actions of a wide orientation.

A METHOD of TREATING POLIELEMENTNOM IN PATIENTS WITH CLINICAL MANIFESTATIONS ZINKEVICIENE STATES, including substitution therapy, characterized in that the injected azizol at a dose of 30 to 120 mg per day orally for 10 - 20 days 2 - 3 courses at intervals of 7 to 10 days.

 

Same patents:

The invention relates to medicine and relates to a pharmaceutical composition inhibiting tumor growth

The invention relates to new derivatives of benzimidazole, possessing valuable pharmacological properties, in particular a derivative of benzimidazole of General formula I

< / BR>
(I) where R1in position 4 means fluorine atom, chlorine or bromine, alkyl with 1-4 carbon atoms, cycloalkyl, vermeil, deformity or trifluoromethyl;

R2alkoxyl with 3-5 carbon atoms, substituted imidazolium in position 3, 4 or 5, alkoxyl with 2-5 carbon atoms, a substituted benzimidazole or tetrahydroimidazo in position 2, 3, 4 or 5, 2-(imidazol-1-yl)-ethoxyl provided that R4means 1H-tetrazolyl, alkylsulfonate with 1-4 carbon atoms, benzosulfimide or generalconclusions, unsubstituted or substituted at the nitrogen atom by alkyl with 1-6 carbon atoms, phenyl, cycloalkyl, phenylalkyl, cycloalkylation, bicyclohexyl or the biphenyl alluminare, in which the acyl radical is alkanoyl with 1-7 carbon atoms, alkoxycarbonyl with a total of 2-4 carbon atoms, alkylsulfonyl with 1 to 6 carbon atoms, benzoyl, benzazolyl, generalkonsulin, naphthalenesulfonyl, cycloalkylcarbonyl, phenylalkanoic or Central electoral commissions substituents from the group includes fluorine atom, chlorine or bromine, methyl, methoxy, phthalimido, hemophthalmia, 2-carboxymethylamino or 2-carboxymethylamino, and one carbonyl group in phthalimidopropyl replaced by methylene, alkylamino or dialkylamino, one methylene group in hoofdlijnen may be substituted by one or two alkyl groups, and the phenyl nucleus may be optionally mono - or tizamidine the alkyl or alkoxyl, and the substituents may be the same or different and are wholly or partially gidrirovanny, unsubstituted or substituted by one or two alkyl groups or one tetramethylenebis or pentamethylene group 5-, 6 - or 7-membered, alkylamino or alkenylamine in which one methylene group may be replaced by a carbonyl or sulfonyl, imides bicycloalkyl-2,3-dicarboxylic acid and imine bicycloalkyl-2,3-dicarboxylic acid, where bicycloalkanes and bicycloalkanes part can contain 9 or 10 carbon atoms can be substituted by 1, 2 or 3 methyl groups, and endometrioma group may be replaced by oxygen atom, amidinopropane, unsubstituted or substituted by one or two alkyl groups is whether the two alkyl groups or tetramethylene or pentamethylene, maleinimide, unsubstituted or mono - or disubstituted by identical or different substituents from among alkyl and phenyl, linked through a carbon atom or aminogroup 5-membered heteroaromatic ring containing aminogroup, oxygen atom or sulfur, or aminogroup and atom oxygen, sulfur or nitrogen, or bound via a carbon atom of the 6-membered heteroaromatic ring containing 1 or 2 nitrogen atom, and mentioned heteroaromatic rings in the carbon skeleton may be substituted by alkyl with 1-6 carbon atoms or phenylalkyl to 5-membered and 6-membered heteroaromatic ring connected n-propylene, n-butylene or 1,3-butadienyl group via two adjacent carbon atom or n-propylene or n-butylene group through aminogroup and the adjacent carbon atom, resulting anilinophenol pyridine ring one methylene group may be replaced by a nitrogen atom, venelinova group in position 3 or 4 to the nitrogen atom of the formed pyridine ring with the sulfur atom, or formed anilinophenol phenyl ring by one or two methyl groups may be replaced by nitrogen atoms, and mentioned precondensation aromatic or heteroalkyl, alkoxyl, hydroxyl, phenyl, nitro, amino, alkylamino, dialkylamino, alkanolamine, cyano, carboxyla, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminoalkyl, formation, deformation, trifluoromethyl, alkanoyl, aminosulfonyl, alkylaminocarbonyl or dialkylaminoalkyl, or tizamidine fluorine atoms or chlorine, stands, metaxylem or hydroxyl, and two methyl substituent can be connected to each other in position 1,2 via a methylene or ethylene bridge, and available if needed in the imidazole ring NH group may be substituted by an alkyl group with 1-6 carbon atoms, phenylalkyl or cycloalkyl; bound through a carbon atom pyrolidine, piperidine or pyridine ring, and the pyridine ring via two adjacent carbon atoms may be precondensation phenyl, and the neighboring nitrogen atom of the methylene group in pyrolidine or piperidinium the ring may be replaced by carbonyl, imidazolidinedione group, unsubstituted or substituted alkyl, phenylalkyl, tetramethylene, pentamethylene or hexamethylene, pyridazin-3-one and dihydropyridin-3-one, which is in position 2 can be substituted and,

the group R7-NR6CO NR5where R5a hydrogen atom, alkyl with 1-8 carbon atoms, cycloalkyl with 5-7 carbon atoms or phenylalkyl;

R6a hydrogen atom, alkyl with 1-8 carbon atoms, alkenyl with 3-5 carbon atoms, phenyl, phenylalkyl or cycloalkyl with 5-7 carbon atoms,

R7a hydrogen atom or alkyl with 1-6 carbon atoms,

one of the radicals R5, R6or R7may mean bicyclohexyl or diphenylol, R6and R7together with the enclosed nitrogen atoms means the unbranched alkalinising with 4-6 carbon atoms, or R5and R6ashamed mean alkylen with 2-4 carbon atoms, 1H, 3H-hinzelin-2,4-Dion-3-yl, pentamethylene-oxazoline-2-yl, or R1a hydrogen atom or is in position 5, 6 or 7 atoms fluorine, chlorine or bromine, an alkyl group with 1-4 carbon atoms, vermeil, deformity or trifluoromethyl; R2bound through a carbon atom or aminogroup 5-membered heteroaromatic ring containing aminogroup and the oxygen atom or sulfur, or aminogroup and atom oxygen, sulfur or nitrogen, or bound via a carbon atom of the 6-membered heteroaromatic ring containing 1 or 2 nitrogen atom, and said heteroaromatics and 6-membered heteroaromatic ring connected n-propylene, n-butylene or 1,3-butadienyl group via two adjacent carbon atom, or n-propylene or n-butylene group through aminogroup and the adjacent carbon atom, resulting anilinophenol pyridine ring one methine group may be replaced by a nitrogen atom, venelinova group in position 3 or 4 to the nitrogen atom formed piperidino ring sulfur atom, or formed anilinophenol phenyl ring, one or two methine groups may be replaced by nitrogen atoms, and mentioned precondensation aromatic or heteroaromatic rings in the carbon skeleton may additionally be monogamist fluorine atom, chlorine or bromine, the alkyl, alkoxyl, hydroxyl, phenyl, nitro, amino, alkylamino, dialkylamino, alkanolamine, cyano, carboxyla, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminoalkyl, formation, deformation, trifluoromethyl, alkanoyl, aminosulfonyl, alkylaminocarbonyl or dialkylaminoalkyl, or tizamidine fluorine atoms or chlorine, stands, metaxylem or hydroxyl, and two methyl substituent can be connected to each other in position 1,2 via a methylene or ethylene my with 1-6 carbon atoms, phenylalkyl or cycloalkyl; bound through a carbon atom pyrolidine, piperidine or pyridine ring, and the pyridine ring via two adjacent carbon atoms may be precondensation phenyl, and the neighboring nitrogen atom of the methylene group in pyrolidine or piperidinium the ring may be replaced by carbonyl,

R3a hydrogen atom, an alkyl group with 1-5 carbon atoms in which one methylene group may be replaced by oxygen atom or sulfur, or cycloalkyl with 3-5 carbon atoms,

R4carboxyl, cyano, 1H-tetrazolyl, 1-triphenyl-methyl-tetrazolyl, alkoxycarbonyl with the total number of carbon atoms 2-5, alkanesulfonyl, arylsulfonamides, triftormetilfullerenov, and if nothing else is specified, then the above alcoolica, alkyl and CNS part can contain 1-3 carbon atoms, and cycloalkyl part of 3-7 carbon atoms, and moreover, if (a) R1a hydrogen atom, R3N-propyl and R4carboxyl, R2in position 6 does not mean 3-methylimidazo[4,5-b]pyridine-2-yl or 3-n-hexyl-imidazo[4,5-b]pyridine-2-yl, or if (b) R1a hydrogen atom, R3n-propyl or n-butyl and R41H-tetraza the sawdust and R4carboxyl, R2in position 5 or 6 does not mean 1-methylbenzimidazole-2-yl or 6 position 1H-butylbenzothiazole-2-yl, 1,5-dimethylbenzimidazole-2-yl or 1-methyl-5-trifluoromethyl-benzimidazole-2-yl, or if g) R1a hydrogen atom, R3n-butyl and R4carboxy or 1H-tetrazolyl, R2in position 6 does not mean 1-methylbenzimidazole-2-yl, or if d) R1a hydrogen atom, R3n-butyl and R4carboxyl, R2in position 6 does not mean benzimidazole-2-yl, mixtures of them 1-, 3-isomers or individual isomers and hydrates and salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases which are used, for example, as antagonists of angiotensin II, the method of obtaining derivatives of benzimidazole containing the substances, medicinal product and method of its production

The invention relates to medicine, in particular to pharmacology and Oncology

The invention relates to medicine, in particular to pharmacology and Oncology

The invention relates to new derivatives of benzimidazole, with a strong pharmacological action, as well as to intermediate compounds for their production

The invention relates to new biologically active compounds, namely, the derivative of 4-aminophenol of the formula I

XNROR1where R1represents a group WITH/ABOUT/УZ;

Y represents a single bond, 0, NR7or; Z represents hydrogen, pyridyl; phenyl which may be substituted with halogen, nitro, lower alkoxy or carboxy; lower alkyl which may be substituted by hydroxy, lower acyloxy, carboxy, lower alkoxycarbonyl, CONR8R9, phenyl/lower/ alkoxy, phenyl, halogen, cyano or NR10R11;

R2, R3, R5and R6that may be the same or different, represent hydrogen, lower alkyl or alkenyl, lower alkoxy or halogen;

R4and R7that may be the same or different, represent hydrogen or lower alkyl;

X 4.5-dihydropyrazolo or pyrazolyl, which may be substituted WITH3-C6-cycloalkyl or phenyl which can be substituted by trihalomethyl;

R8, R9, R10, R11which may be the same or different, represent hydrogen, lower alkyl or benzyloxycarbonyl, or their N-alkyl

The invention relates to medicine, namely to urology, and pulmonology, and can be used in the treatment of tuberculosis of the urinary system

The invention relates to medicine and for the production of the antidote

FIELD: organic chemistry, medicine, dermatology.

SUBSTANCE: invention relates to zinc and aliphatic halogen-carboxylic acid salts that can be used in treatment of benign neoplasms of skin and visible mucosa tissues. Invention proposes the following formula of zinc and aliphatic halogen-carboxylic acid salts: (1): wherein R means -CHal3, -CHHal2, -CH2Hal and (2): wherein R' means Alk, hydrogen atom (H); R'' means Hal; R' means Alk; R'' means H, Alk wherein in these formulae halogen atom can be represented by fluorine atom (F), chlorine atom (Cl), bromine atom (Br) or iodine atom (J). Invention provides the development of original preparation used in treatment of benign neoplasms of skin and visible mucosa tissues with low toxicity, rapid effect, expressed therapeutic effect and eliciting good tolerance, absence of complications in treatment, healing without formation of scar tissue. The development of the preparation provides expanding assortment of agents used in treatment of such diseases.

EFFECT: enhanced and valuable properties of agents.

13 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with applying a multi-purpose complex preparation that contains the following components in 1 l of distilled water: sodium selenite 1.0; vitamin E/in the form of combinal E/7500 mg; succinic acid 10.0; zinc sulfate 10.0 and pharmazine 50000 U. The preparation should be introduced as intramuscular injections 45, 30, 15 d before delivery and during the day of delivery: in cows per 10-15 ml, for pigs and sheep per 5 ml, for youngsters after the birth: in calves - 5 ml, in piglets and lambs per 1-2 ml, in hens per 0.5 ml once/2 wk. The innovation is very efficient in increasing the quality and quantity of production, improving the growth and development in fetus and offspring, preventing some surgical and obstetric-gynecological pathologies.

EFFECT: higher efficiency of correction.

5 cl

FIELD: veterinary science.

SUBSTANCE: invention relates to a composition used in prophylaxis and treatment of anemia in agricultural animals and poultry that comprises a mixture of chelates of iron, copper, zinc, cobalt, sodium, calcium with ethylenediamine-N,N'-disuccinic acid in the following ratio of components, wt.-%: copper chelates with ethylenediamine-N,N'-disuccinic acid, 0.45-0.60; zinc chelates with ethylenediamine-N,N'-disuccinic acid, 1.40-1.45; cobalt chelates with ethylenediamine-N,N'-disuccinic acid, 0.075-0.08; sodium chelates with ethylenediamine-N,N'-disuccinic acid 42.0-44.0; calcium chelates with ethylenediamine-N,N'-disuccinic acid, 12.0-13.0, and iron chelates with ethylenediamine-N,N'-disuccinic acid, the balance. Agent provides enhancing the blood hemoglobin content in animals by 28% as compared with animals receiving neither anti-anemic agents and by 12% as compared with animals receiving the preparation-analog.

EFFECT: enhanced effectiveness of composition.

4 tbl, 4 ex

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with obtaining compositions being of bactericidal, antiphlogistic, regenerating, antioxidant and antimicrobial properties at no allergic action. Wound-healing preparation (variant 1) contains: stearic acid 4.5-6.0; purified lanolin and its derivatives 3.0-6.0; vegetable oil 3.0-5.0; Vaseline 1.5-2.5; glycerol 4.0-8.0; castor oil 8.0-12.0; zinc stearate 1.0-2.5; 70%- alcoholic extract of phytospecies 2.5-3.5; extract of common John's wort grass 3.5-8.5; dog rose oil or sea buckthorn oil 2.6-6.0; Na-salts of fatty acids of wool fat 0.3-0.6; triethanolamine 0.7-1.1; anesthesin 2.0-3.0; 10%-butyric solution of propolis 0.3-1.0; boric acid 0.4-0.6; purified water - the rest. Wound-healing preparation (variant 2) contains: stearic acid 4.5-6.0; purified lanolin and its derivatives 3.0-6.0; vegetable oil 3.0-5.0; Vaseline 1.5-2.5; glycerol 4.0-8.0; castor oil 8.0-12.0; zinc stearate 1.0-2.5; 70%-alcoholic extract of phytospecies 2.5-3.5; extract of common John's wort 3.5-8.5; dog rose oil or sea buckthorn oil 2.6-6.0; Na-salts of fatty acids of wool fat 0.3-0.6; triethanolamine 0.7-1.1; anesthesin 2.0-3.0; levomycetin or gentamycine 2.0-3.0; 10%-butyric solution of propolis 0.3-1.0; boric acid 0.4-0.6; purified water - the rest. Additional introduction of the extract of common John's wort has increased antioxidant properties; 10%-butyric propolis - antioxidant and bactericidal properties, and levomycetin and gentamycine - has widened the range of antimicrobial action. Application of the preparation suggested in patients with burns and wounds revealed positive therapeutic effect without any cicatricial neoplasms and allergic action. No contraindications had been established.

EFFECT: higher efficiency of application.

4 cl, 8 ex

FIELD: medicine.

SUBSTANCE: invention relates to application of Acizol, namely bis(1-vinylimidazole) zinc diacetate as coronary active anti-ischemia and anti-arrhythmia agent. Acizol makes it possible to limit development of necrosis zone in acute myocardium ischemia, to reduce frequency of complications and fatal cases, to normalize antrioventricular and intraventricular electrical conductivity , to prevent ciliary arrythmia.

EFFECT: improved anti-ischemia and anti-arrhythmia agent.

15 tbl, 7 dwg, 6 ex

FIELD: medicine.

SUBSTANCE: method involves administering Acizol (bis1-vinyl imidazole zinc diacetate).

EFFECT: stable remission; improved bone tissue resorption in postoperative period; accelerated periodontium tissue recovery.

3 dwg, 3 tbl

FIELD: chemical-pharmaceutical industry, metalloorganic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to polyacrylic acid incomplete zinc salt corresponding to the formula: (-CH2-CHCOOH-)n(-CH2CHCOOZn0.5-)m wherein n = 12000-35000; m = 1650-6650 wherein the content of zinc is (6-8 wt.-%) 0.0009-0.0012 g-at, the content of carboxyl groups is 0.0117-0.0122 g-equv/1 g of polymer, and molecular mass is in the limits 1000000-3000000 Da. Also, invention proposes a method for preparing this salt that involves addition of zinc acetate aqueous solution to polyacrylic acid solution, stirring the reaction mixture for 120-300 min and drying the prepared solution under vacuum at temperature 50°C, not above. Agent is prepared as a solution in the ratio 1-10 g of polyacrylic acid incomplete zinc salt in 100 ml of water. Agent shows antiseptic, hemostatic and wound-healing effect in its external using.

EFFECT: improved preparing method, valuable medicinal properties of agent.

3 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: it is necessary to carry out complex medicinal therapy including specific antiviral preparations, group B-vitamins, immunocorrectors, injection of antiherpetic vaccine, and, also local therapy with derinate. Additionally, since the 1st d of exacerbation it is important to inject flosteron once i/m at 1.0 ml, cefotaxym i/m twice daily per 1.0 mg for 10 d. Immunomodulator halavit on the 1st d should be prescribed i/m at the dosage of 200 mg, and then for the next 15 d - twice daily per 100 mg i/m. Diazepam for 1 mo should be injected per 5.0 mg 4 times daily, and then per 2.5 mg 4 times daily for 1 mo, as well. One should daily inject atarax per 100 mg nocturnally for 1 mo and ketorol internally per 10 mg thrice daily for 10 d. Moreover, it is necessary to apply the composition out of 50.0 g zinc oxide, 5.0 ml ACD fraction and 25.0 g "Aciclovir" cream 4 times daily for 10 d. The innovation enables to considerably increase the efficiency of therapy due to improving the main immunological values, weakening local autoimmune reactions and, also, preventing the development of psychic disorders in such patients due to affecting viral neurotropic properties.

EFFECT: higher efficiency of therapy.

3 dwg, 1 ex

FIELD: medicine; dental surgery.

SUBSTANCE: for this purpose first of all root canals are filled with paste based on eugenol, zinc oxide, dry iodoform and lincomycin hydrochloride taken in ratio 3:3:1:1. Then cortical plate trepanation and cyst membrane extraction are followed with ultrasonic treatment of bone cavity through 0.05% miramistine within 5 minutes using ultrasonic device US-102 at exposure intensity 0.05-0.4 Wt/cm in pulse mode. Treated bone cavity is introduced with filling-bandage "Collost" and with mixed osteoplastic gel "Collost" and lincomycin hydrochloride taken in ratio 2:1, and is covered with membrane "Collost". Wound is isolated from mouth cavity with film "Dyplene-denta" with lincomycin.

EFFECT: enables to accelerated wound healing process due to complete osteointegration and angioosteogenesis of implanted material.

4 ex

FIELD: medicine; pharmacology.

SUBSTANCE: composition for prevention and treatment of asthma and upper airways diseases is characterised by that it includes incense tree Boswellia serrata dry extract solution with Boswellia acids content in terms of β- Boswellia acid not less than 80%, in wheat germs oil mixed with pharmaceutically acceptable selenium source and encapsulated containing glycerine, gelatin, pharmaceutically acceptable zinc source and chicory dry extract. Composition production implies that pharmaceutically acceptable zinc source, chicory dry extract gelatin, glycerine are sequentially dissolved renovated water. Agitated mixture is used to make capsule thereafter filled with capsulation solution produced by stirring of wheat germs oil and pharmaceutically acceptable selenium source followed by gradual addition of incense tree Boswellia serrata dry extract, with Boswellia acids content in terms of β- Boswellia acid not less than 80% till it is completely dissolved. Produced capsules are kept at temperature 5-10°C and dried out.

EFFECT: produced composition has improved efficiency.

4 cl, 4 ex

Up!